Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
PepGen is empowering nucleic acid therapeutics to go the distance.
KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Metalex Commodities is a commodity trading company that specializes in the export of metal ores and concentrates.
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Forge Biologics is a gene therapy development engine, enabling access to life changing gene therapy programs.
Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.
Navigator Medicines operate as a biotech company.
Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Empatica is an affective computing company focused on human data analytics.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $43.0B.
RA Capital Management's average investment size is $126.1M across its portfolio of 453 companies.
Recent RA Capital Management portfolio additions include IO Biotech, Aktis Oncology, ARS Pharmaceuticals, Pepgen, KalVista Pharmaceuticals. These companies were founded in 2020 or later.